Cargando…
COST ANALYSIS FOR USE OF PROCALCITONIN AND INFLAMMATORY MARKERS IN COVID-19 VENTILATOR-ASSOCIATED PNEUMONIA
Autores principales: | KIM, A., VAN, A., MEHTA, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212670/ http://dx.doi.org/10.1016/j.chest.2021.12.150 |
Ejemplares similares
-
ROLE OF PROCALCITONIN IN PATIENTS WITH COVID-19 AND HOSPITAL-ACQUIRED PNEUMONIA
por: KUMAR, MYTHRI ANIL, et al.
Publicado: (2022) -
ABO BLOOD TYPES AND INFLAMMATORY MARKERS IN COVID-19 PNEUMONIA
por: GO, R., et al.
Publicado: (2022) -
UPFRONT COMMUNITY-ACQUIRED PNEUMONIA ANTIMICROBIAL THERAPY IS ASSOCIATED WITH REDUCED RATES OF VENTILATOR-ASSOCIATED PNEUMONIA IN PATIENTS WITH COVID-19
por: WAKEFIELD, CONNOR, et al.
Publicado: (2022) -
POOR PROGNOSTIC VALUE OF INFLAMMATORY MARKERS IN COVID-19 PNEUMONIA: A RETROSPECTIVE ANALYSIS
por: GREWAL, S., et al.
Publicado: (2022) -
A COMPARISON OF THE INCIDENCE OF VENTILATOR-ASSOCIATED PNEUMONIA AMONG PATIENTS WITH COVID-19 AND INFLUENZA PNEUMONIA A AND B
por: GROSSMAN, J., et al.
Publicado: (2022)